Benaglutide/insulin glargine - Shanghai Benemae Pharmaceutical
Alternative Names: BEM-041Latest Information Update: 05 Sep 2022
At a glance
- Originator Shanghai Benemae Pharmaceutical
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Type 2 diabetes mellitus
Most Recent Events
- 21 Jul 2022 Early research in Type 2 diabetes mellitus in China (unspecified route) (Shanghai Benemae Pharmaceutical pipeline, July 2022)